UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 225

Sortiert nach

The Evolving Landscape of Immunotherapy-Based Combinations for Frontline Treatment of Advanced Renal Cell Carcinoma

Frontiers in immunology, 2019-01, Vol.9, p.3120-3120

2019

Link zum Volltext

Verfügbarkeit prüfen

Nivolumab Monotherapy and Nivolumab Plus Ipilimumab in Recurrent Small Cell Lung Cancer: Results From the CheckMate 032 Randomized Cohort

Journal of thoracic oncology, 2020-03, Vol.15 (3), p.426-435

2020

Link zum Volltext

Verfügbarkeit prüfen

A Randomized, Double-Blind, Placebo-Controlled, Phase II Study Comparing the Tolerability and Efficacy of Ipilimumab Administered with or without Prophylactic Budesonide in Patients with Unresectable Stage III or IV Melanoma

Clinical cancer research, 2009-09, Vol.15 (17), p.5591-5598

2009

Link zum Volltext

Verfügbarkeit prüfen

Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study

Journal for immunotherapy of cancer, 2018-10, Vol.6 (1), p.109-109, Article 109

2018

Link zum Volltext

Verfügbarkeit prüfen

Immune checkpoint inhibitors in clinical practice: update on management of immune-related toxicities

Translational lung cancer research, 2015-10, Vol.4 (5), p.560-575

2015

Link zum Volltext

Verfügbarkeit prüfen

Skin Manifestations Associated with Kidney Cancer

Seminars in oncology, 2016-06, Vol.43 (3), p.408-412

2016

Link zum Volltext

Verfügbarkeit prüfen

Big data-assisted social media analytics for business model for business decision making system competitive analysis

Information processing & management, 2022-01, Vol.59 (1), p.102762, Article 102762

2022

Link zum Volltext

Verfügbarkeit prüfen

Interleukin-2 in Renal Cell Carcinoma: A Has-Been or a Still-Viable Option?

Journal of kidney cancer and VHL, 2014-01, Vol.1 (7), p.74-83

2014

Link zum Volltext

Verfügbarkeit prüfen

Spectrum and prevalence of BRCA1/2 germline mutations in Pakistani breast cancer patients: results from a large comprehensive study

Hereditary cancer in clinical practice, 2019-09, Vol.17 (1), p.27-27, Article 27

2019

Link zum Volltext

Verfügbarkeit prüfen

Two-Stage Cooperative Intelligent Home Energy Management System for Optimal Scheduling

IEEE transactions on industry applications, 2022-07, Vol.58 (4), p.5423-5437

2022

Link zum Volltext
IEEE_Xplore

Nivolumab monotherapy or combination with ipilimumab with or without cobimetinib in previously treated patients with pancreatic adenocarcinoma (CheckMate 032)

Journal for immunotherapy of cancer, 2024-02, Vol.12 (2), p.e007883

2024

Link zum Volltext

Verfügbarkeit prüfen

Renewable Energy Maximization for Pelagic Islands Network of Microgrids Through Battery Swapping Using Deep Reinforcement Learning

IEEE access, 2023, Vol.11, p.86196-86213

2023

Link zum Volltext

Verfügbarkeit prüfen

Phase II study of vemurafenib followed by ipilimumab in patients with previously untreated BRAF-mutated metastatic melanoma

Journal for immunotherapy of cancer, 2016-08, Vol.4 (1), p.44-44, Article 44

2016

Link zum Volltext

Verfügbarkeit prüfen

Correction to: Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study

Journal for immunotherapy of cancer, 2019-03, Vol.7 (1), p.73-73, Article 73

2019

Link zum Volltext

Verfügbarkeit prüfen

Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma

The New England journal of medicine, 2022-01, Vol.386 (1), p.24-34

2022

Link zum Volltext

Verfügbarkeit prüfen

First-line vascular endothelial growth factor targeted therapy in renal cell carcinoma: priming the tumor microenvironment for immunotherapy

Current medical research and opinion, 2018-05, Vol.34 (5), p.825-831

2018

Link zum Volltext

Verfügbarkeit prüfen

Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma

The New England journal of medicine, 2019-03, Vol.380 (12), p.1116-1127

2019

Link zum Volltext

Verfügbarkeit prüfen

A market-based real-time algorithm for congestion alleviation incorporating EV demand response in active distribution networks

Applied energy, 2024-02, Vol.356, p.122426, Article 122426

2024

Link zum Volltext

Verfügbarkeit prüfen

Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial

The lancet oncology, 2019-10, Vol.20 (10), p.1370-1385

2019

Link zum Volltext

Verfügbarkeit prüfen

Safety and Efficacy of Nivolumab in Combination With Ipilimumab in Metastatic Renal Cell Carcinoma: The CheckMate 016 Study

Journal of clinical oncology, 2017-12, Vol.35 (34), p.3851-3858

2017

Link zum Volltext

Verfügbarkeit prüfen

SD-101 in Combination with Pembrolizumab in Advanced Melanoma: Results of a Phase Ib, Multicenter Study

Cancer discovery, 2018-10, Vol.8 (10), p.1250-1257

2018

Link zum Volltext

Verfügbarkeit prüfen

Neoadjuvant Nivolumab for Patients With Resectable Merkel Cell Carcinoma in the CheckMate 358 Trial

Journal of clinical oncology, 2020-08, Vol.38 (22), p.2476-2487

2020

Link zum Volltext

Verfügbarkeit prüfen

Venous thromboembolism incidence and risk factors in non-small cell lung cancer patients receiving first-line systemic therapy

Thrombosis research, 2021-12, Vol.208, p.71-78

2021

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 225

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(190)
Mit Volltextzugriff
(206)

Publikationsform

Sprache

Englisch
(224)
Japanisch
(5)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 7 Tagen
(1)
... seit 90 Tagen
(5)

Menü

Weitere Dienste

Einstellungen

The Evolving Landscape of Immunotherapy-Based Combinations for Frontline Treatment of Advanced Renal Cell Carcinoma

Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial

Nivolumab Monotherapy and Nivolumab Plus Ipilimumab in Recurrent Small Cell Lung Cancer: Results From the CheckMate 032 Randomized Cohort

A Randomized, Double-Blind, Placebo-Controlled, Phase II Study Comparing the Tolerability and Efficacy of Ipilimumab Administered with or without Prophylactic Budesonide in Patients with Unresectable Stage III or IV Melanoma

Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial

Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study

Immune checkpoint inhibitors in clinical practice: update on management of immune-related toxicities

Skin Manifestations Associated with Kidney Cancer

Big data-assisted social media analytics for business model for business decision making system competitive analysis

Interleukin-2 in Renal Cell Carcinoma: A Has-Been or a Still-Viable Option?

Spectrum and prevalence of BRCA1/2 germline mutations in Pakistani breast cancer patients: results from a large comprehensive study

Two-Stage Cooperative Intelligent Home Energy Management System for Optimal Scheduling

Nivolumab monotherapy or combination with ipilimumab with or without cobimetinib in previously treated patients with pancreatic adenocarcinoma (CheckMate 032)

Renewable Energy Maximization for Pelagic Islands Network of Microgrids Through Battery Swapping Using Deep Reinforcement Learning

Phase II study of vemurafenib followed by ipilimumab in patients with previously untreated BRAF-mutated metastatic melanoma

Correction to: Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study

Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma

First-line vascular endothelial growth factor targeted therapy in renal cell carcinoma: priming the tumor microenvironment for immunotherapy

Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma

A market-based real-time algorithm for congestion alleviation incorporating EV demand response in active distribution networks

Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial

Safety and Efficacy of Nivolumab in Combination With Ipilimumab in Metastatic Renal Cell Carcinoma: The CheckMate 016 Study

SD-101 in Combination with Pembrolizumab in Advanced Melanoma: Results of a Phase Ib, Multicenter Study

Neoadjuvant Nivolumab for Patients With Resectable Merkel Cell Carcinoma in the CheckMate 358 Trial

Venous thromboembolism incidence and risk factors in non-small cell lung cancer patients receiving first-line systemic therapy

Suchergebnisse filtern